VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | Addressing the issue of resistance to TKIs in CML

Giuseppe Saglio, MD, University of Turin, Turin, Italy, describes known mechanisms of resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), highlighting the efficacy of ponatinib and asciminib in patients carrying the T315I mutation, and emphasizing the importance of better understanding the role of mutations in other genes than BCR-ABL1 in resistance to TKIs. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter